Alerts will be sent to your verified email
Verify EmailASTRAZEN
Astrazeneca Pharma I
|
Fortis Healthcare
|
Artemis Medicare
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
18.6 % | n/a | n/a |
R&D as a % of Total Sales
|
0.0 | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
17.46 % | 2.33 % | 7.55 % |
5yr average Equity Multiplier
|
1.97 | 1.73 | 2.07 |
5yr Average Asset Turnover Ratio
|
0.99 | 0.44 | 0.81 |
5yr Avg Net Profit Margin
|
9.04 % | 2.18 % | 4.33 % |
Price to Book
|
22.44 | 4.64 | 5.45 |
P/E
|
98.89 | 59.32 | 49.73 |
5yr Avg Cash Conversion Cycle
|
-120.04 Days | -133.71 Days | -108.41 Days |
Inventory Days
|
63.93 Days | 6.17 Days | 6.72 Days |
Days Receivable
|
35.03 Days | 31.7 Days | 39.07 Days |
Days Payable
|
229.92 Days | 220.67 Days | 166.71 Days |
5yr Average Interest Coverage Ratio
|
104.17 | 3.83 | 3.17 |
5yr Avg ROCE
|
23.44 % | 4.56 % | 8.78 % |
5yr Avg Operating Profit Margin
|
15.59 % | 14.05 % | 12.74 % |
5 yr average Debt to Equity
|
0.0 | 0.19 | 0.48 |
5yr CAGR Net Profit
|
12.77 % | n/a | 19.95 % |
5yr Average Return on Assets
|
8.84 % | 1.32 % | 3.58 % |
Shareholdings
|
|||
Promoter Holding
|
75.0 % | 31.17 % | 68.03 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -1.79 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.92 % | 14.26 % | 0.79 % |
Astrazeneca Pharma I
|
Fortis Healthcare
|
Artemis Medicare
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|